Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

The Expert: Many air purifiers are completely useless

An article in Dagens PS interviewed Anders Hedström, who has worked with air purification for most of his working life. Most recently as global head of air quality at Swedish Camfil AB, which is a world leader in filters for air purification. Today, he is an advisor to the WHO's Collaboration Center at Queensland University of Technology and works, among other things, to develop a new standard for air purification, and also as a consultant to the aviation industry regarding air purification.He believes that many air purifiers are largely ineffective. It is required, among other things, that

Disclosure of 5 percent holding of own shares

Zurich, Switzerland, November 6, 2020On November 4, 2020, ABB held 109,359,211 of its own shares, which corresponds to 5.04 percent of total share capital and voting rights in the company. This includes 89,326,859 shares purchased for capital reduction purposes as part of its share buyback program announced on July 22, 2020. ABB’s total number of issued shares, including shares held in treasury, amounts to 2,168,148,264. Additional information is available on ABB’s investor relations website site at https://global.abb/group/en/investors/investor-and-shareholder-resources/share-buyback-

SAS Traffic figures - October 2020

The ongoing pandemic continues to severely impact SAS and reported traffic figures for October are broadly in line with September this year.During the month, SAS carried just over 0.6 million passengers, down 78.7% compared to last year. Similarly, SAS reduced its capacity by 73.3% year-over-year. Compared to the previous month, demand, capacity and load factor remained broadly unchanged. “Reported traffic is close to what we experienced in September and demand continues to be stronger for domestic than for European and Intercontinental travel, which is also reflected in the network and

Elkem Silicones signs strategic pacts and showcases top technologies and products, at CIIE 2020.

Shanghai, November 6, 2020 - One of the pioneers in manufacturing silicones, and a technology leader with over six decades of history in the silicone industry, Elkem Silicones is showcasing its wide range of innovative technologies and solutions at the 3rd China International Import Expo (CIIE 2020). For the first time, during this worldwide event, Elkem Silicones is signing strategic pacts, having a total contract value of more than CNY 1 billion with multiple Chinese customers. The silicone technologies and products on show have applications in personal protection, automotive, construction,

Bulletin from the extraordinary shareholders’ meeting in SynAct Pharma AB

Today, on 6 November 2020, an extraordinary shareholders’ meeting was held in SynAct Pharma AB. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority.Election and remuneration to the board of directors The meeting resolved in accordance with the shareholders’ proposal that the board of directors shall consist of five ordinary board members without deputy board members, to elect Uli Hacksell as new ordinary board member for the period until the next annual shareholders’ meeting along with the current board members and that board

BERGENBIO HOSTING VIRTUAL R&D DAY TODAY

Bergen, Norway, 06 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that it is hosting a Virtual R&D Day today. The online event will begin at 13.00pm CET (04.00am PST/06.00am CST). Please click here (bergenbio@consilium-comms.com?subject=I%20would%20like%20to%20attend%20the%20BerGenBio%20Virtual%20Event) to register. The event will feature experts from academic institutions across Europe and the US, highlighting the role of AXL kinase as an

OM Pharma and AstraZeneca enter into strategic collaboration to expand presence in respiratory and immunology fields in China

OM Pharma enters into a strategic collaboration agreement granting AstraZeneca the exclusive right to import and distribute the immunological therapy Broncho-Vaxom[® ]for the prevention and treatment of respiratory tract infections in China (excluding Hong Kong, Macau, and Taiwan).Meyrin/Geneva, Switzerland, 6 November 2020 – OM Pharma and AstraZeneca celebrated their strategic collaboration agreement today at a partnership signing ceremony in Shanghai. The strategic collaboration agreement grants AstraZeneca the exclusive right to import, distribute and promote OM Pharma’s Broncho-Vaxom[

Cessatech A/S receives approval for listing and publishes prospectus

Cessatech A/S (“Cessatech” or the “Company”) today announces that Spotlight Stock Market’s listing committee has approved Cessatech’s application for admission to trading of the Company’s shares on Spotlight Stock Market. The approval is given under the condition that the Company raises the minimum limit and that the Company obtains a sufficient number of shareholders in accordance with Spotlight Stock Market’s listing agreement in the upcoming initial public offering (IPO). Cessatech today also publishes the prospectus for the upcoming issue of units, for which the subscription period starts

Veidekke ASA: Constructing logistics hubs at Vestby

Veidekke Logistikkbygg has signed a contract with Pareto Eiendomsfellesskap AS for the construction of Nordisk Dækimport’s (NDI) new central warehouse facility at Vestby to the south of Oslo. The contract is a turnkey contract valued at approx. NOK 185 million excluding VAT.The project involves the co-location of NDI’s existing warehousing facilities in Eastern Norway to the Vestby Business Park East in the municipality of Vestby. Pareto, NDI and Veidekke have worked closely together to develop a building that satisfies the requirements for a modern, efficient logistics hub. The building

The following primary insider in Multiconsult ASA has purchased shares in Multiconsult ASA:

Hans-Jørgen Wibstad, Chief Financial Officer/CFO of Multiconsult ASA, has on 6 November 2020 purchased 1,250 shares in Multiconsult ASA at a price of NOK 112.00 per share and will after the transaction holds 6,433 shares in Multiconsult ASA.For further information, please contact     Gaute Christensen, VP Communications    Phone: +47 911 70 188            E-mail: gaute.christensen@multiconsult.no  This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

Swedavia’s traffic statistics for October 2020

During October, 743,000 passengers flew via Swedavia’s ten airports, a decrease of 79 per cent compared to 3,531,000 passengers for the same period last year. Travel for the autumn vacation contributed to a certain recovery in October, but the demand for flights is still at historical lows. New restrictions in Europe are contributing to renewed uncertainty about market prospects in the near time. Of the total 743,000 passengers in October, 427,000 were international passengers, which is a decrease of 82 per cent compared to 2,378,000 for the same period last year. Domestic travel

Many possibilities for carbon dioxide in biogas plants – carbon dioxide emissions recycling concept being studied in Päijät-Häme in Finland

LAB University of Applied Sciences (LAB), LUT University (LUT) and Lahti Region Development LADEC are studying a regional carbon dioxide emissions recycling concept in Päijät-Häme. A capture and purification pilot aimed at utilizing recycled carbon dioxide (biocarbon dioxide) is under way in partnership with Päijät-Häme Waste Management (PHJ) at the Kujala waste center in Lahti, LABIO Oy and Gasum.The carbon capture pilot is part of the BIOSYKLI project, which is studying the largest regional producers of carbon dioxide and regional users for captured and purified carbon dioxide. The carbon

Lindex’s customers donate 1.2 million euro to cancer research

With joined forces and great commitment, Lindex has together with its customers raised 1.2 million euro to cancer research.    “Thanks to the fantastic commitment of our employees and customers, we show once again that when we unite our efforts we can make a difference. It feels important that we together can contribute to cancer research so more people can survive and less people are affected by cancer”, says Susanne Ehnbåge, Lindex CEO. During the first weekend in October, Lindex donated 10 percent of the sales on all 18 markets and on lindex.com to cancer research. Lindex

Peab refurbishes the port in Köping

Peab has been commissioned to dredge Köping Port and then handle the dredged material. The customer is Köping Municipality and the contract is worth SEK 170 million.The project entails dredging up an area of around 4.5 kilometers on the outer edge of the port area in Köping. The project also includes dredging three other areas in the shipping lane. This will be done primarily to widen and ensure the proper depth along the shipping lane’s outer edges. It will generate a total of around 250,000 m2 dredged material. The polluted dredged material will be encapsulated so that it can then be

Notification of Extraordinary General Meeting in DNB ASA

Shareholders in DNB ASA are invited to attend the Extraordinary General Meeting to be held on Monday 30 November 2020 at 15:00.  Due to the corona situation, the Extraordinary General Meeting will be held digitally, using electronic voting.  Agenda: Proposals to merge with DNB Bank ASA, authorisation to the Board of Directors to decide a dividend for 2019 of up to NOK 9 per share, and authorisation to the Board of Directors to buy back shares. The notice of the Extraordinary General Meeting is attached.  Company information This information is subject to the disclosure

Prebona proves unique, long-term effect against COVID-19/SARS CoV-2

Independent test-institutes have confirmed that Prebona Disinfect is extremely effective against the coronavirus - SARS CoV-2, COVID-19. The tests, conducted on textiles, shows that before and even after 10 machine washes, Prebona Disinfect still eliminates 99,99% of virus particles after 60 minutes. 99% of the virus particles are eliminated after three minutes, and 99,99% after 60 minutes. All tests have been conducted in accordance with the global standard ISO 18184:2019 - These are truly excellent results, verifying the strength in our patented technology and also proving a

Senzime’s Interim report January – September 2020

Press release: Uppsala, November 6, 2020. Senzime AB’s (publ) Interim report for January – September 2020 is now available on the company’s website  www.senzime.comFinancial information for the third quarter 2020 · Net sales amounts to KSEK 2,096 (2,420) · Income after financial items amounts to KSEK -11,787 (-7,473) · Earnings per share amounts to SEK -0.20 (-0.14) Financial information for January-September 2020 · Net sales amounts to KSEK 5,843 (4,023) · Income after financial items amounts to KSEK -33,420 (-24,650) · Earnings per share amounts to SEK -0.58 (-0.

Last day of trading in paid subscribed units (Sw. BTU)

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, November 6, 2020 – Last day of trading in subscribed paid units (“BTU”) in ExpreS[2]ion Biotech Holding AB (publ) (“ExpreS[2]ion” or the “Company”) will be November 10, 2020 and stop day will be on November 12, 2020.

Invitation to Presentation of Immunovia´s Interim Report January – September 2020 on November 12, 2020

LUND (SWEDEN) – Immunovia invites to a teleconference (in English) for investors, analysts and media on Thursday, November 12, 2020 at 16:30 CET. Immunovia will publish the company’s interim report on November 12, 2020 at 16:00 CET. Patrik Dahlen, CEO will present Immunovia and comment on the interim report for the period January – September 2020 followed by a Q&A session. Please call in a few minutes in advance. To attend, please dial-in at one of the numbers below and provide the conference code Immunovia to the operator: Conference Call Sweden: +46 (0) 8 50520424 United

Rejlers wins framework agreement with FMV through NESP

Through its holding in NESP, Rejlers is entering into a new framework agreement with FMV (Swedish Defence Materiel Administration) concerning consultancy services within Integrated Logistics Support (ILS). The agreement runs for up to seven years and has provision for the Swedish Armed Forces to place suborders under the agreement.The new framework agreement with FMV covers consulting services within Integrated Logistics Support (ILS), which is a management process that supports development work in order to dimension and optimise maintenance systems based on requirements regarding

Interim Report April – September 2020

Another quarter with more then 30 percent growthCEO’s comments The second quarter of 2020/21 was another quarter with good growth for EQL Pharma. Sales for the quarter amounted to SEK 24.2 million, an increase of 36%. During the quarter, an order for healthcare consumables, totalling SEK 8 million, was received from a Hospital region. Around 3 MSEK of this order was invoiced during the quarter and the remaining part will be invoiced during the third quarter. The corona epidemic has had a minor impact on our company, where some products sell more than usual due to stock-outs for our

Moberg Pharma decides on fully guaranteed rights issue of approximately SEK 150 million

The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or “the Company”) has today resolved to carry out a fully guaranteed issue of new ordinary shares and warrants (“Units”) with preferential rights for existing shareholders (the “Rights Issue”) of approximately SEK 150 million before transaction costs. The Rights Issue requires the approval of an extraordinary general meeting (the “Extraordinary General Meeting”). The proceeds will be used for registration activities and clinical work for MOB-015. When the Rights Issue is completed, the Company intends to terminate

Brilinta approved in the US in stroke

6 November 2020 07:00 GMT Brilinta approved in the US to reduce the risk of stroke in patientswith an acute ischaemic stroke or high-risk transient ischaemic attack New indication expands use of Brilinta beyond cardiovascular disease to patients with mild-to-moderate stroke AstraZeneca's Brilinta (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk transient ischaemic attack (TIA). The approval by the

Moberg Pharma intends to distribute and separately list BupiZenge[®] (BUPI)

The Board of Directors of Moberg Pharma AB (OMX: MOB) today announces its intention to distribute the operations of BupiZenge[®] (BUPI) to the shareholders of Moberg Pharma by distributing 90 percent of the shares in a subsidiary (name to be changed to OncoZenge AB) through a so-called Lex ASEA distribution, and convenes an extraordinary general meeting to resolve accordingly. The business consists of developing the BUPI project under the brand name BupiZenge[®] for treatment of oral mucositis. Moberg Pharma estimates the capital requirement to take BupiZenge[®] through phase 3 at SEK 60

There are no items matching the current filter
There are no more items matching the current filter
Back to top